20270061: C.H. Boehringer Sohn AG & Co. KG; Ultragenyx Pharmaceutical Inc.
HSR Early Termination Notices ·
20270061: C.H. Boehringer Sohn AG & Co. KG; Ultragenyx Pharmaceutical Inc. Date October 27, 2026 bjames@ftc.gov October 28, 2026 | 10:27AM Transaction Number 20270061 Acquiring Party C.H. Boehringer Sohn AG & Co. KG Acquired Party Ultragenyx Pharmaceutical Inc. Granting Status Granted Acquired Entities Ultragenyx Pharmaceutical Inc.